AVENUE THERAPEUTICS, INC.
AVENUE THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 14, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.
Cash runway is approximately 13.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 14, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
Track ATXI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ATXI in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| February 23, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| November 18, 2025 | 8-K filed: Other event | Filing | — |
| November 12, 2025 | 8-K filed: Material agreement, Leadership change, Other event | Corporate | — |
| April 30, 2025 | 8-K filed: Material agreement, Acquisition completed | Corporate | — |
| May 30, 2019 | Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty | Trial Milestone | Phase 3 |
| April 25, 2019 | Evaluate Safety of Tramadol in the Management of Postoperative Pain Following Surgery | Trial Milestone | Phase 3 |
| April 11, 2018 | Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy | Trial Milestone | Phase 3 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.